ORAL ABSORPTION OF OXYCODONE AFTER CARDIAC BYPASS SURGERY

ORAL ABSORPTION OF OXYCODONE AFTER CARDIAC BYPASS SURGERY - Oksi-postcard

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2011-004894-96-FI

Enrollment

120

Registered

2012-02-08

Start date

2012-03-20

Completion date

Unknown

Last updated

2012-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 14.1 Level: PT Classification code 10058829 Term: Elective surgery System Organ Class: 10042613 - Surgical and medical procedures MedDRA version: 14.1 Level: LLT Classification code 10054366 Term: Coronary revascularization System Organ Class: 10042613 - Surgical and medical procedures

Interventions

Trade Name: Targiniq 20mg/10mg Product Name: Targiniq 20mg/10mg Pharmaceutical Form: Prolonged-release tablet Other descriptive name: Oxycodoni hydrochloridum Concentration unit: mg milligram(s) Conce

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 60 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 60

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Finland

Contacts

Public ContactMikko Hippeläinen

Kuopio University Hospital

mikko.hippelainen@kuh.fi+35817173311

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026